ICHMCR · Registering as Listener

International Conference on Hematologic Malignancies and Cancer Research

4th Mar – 5th Mar 2027 Stockholm, Sweden Standard / Physical Participation
Listener Registration From
$—
$— in person
Registration Benefits:
Official invitation letterIssued automatically after registration
Certificate & digital materialsGet certificate, slides and resource materials
Supporting global researchConnect with researchers across 30+ countries

Select registration mode

Prices are shown before tax and bank charges — no surprises at checkout.

All sessions Networking Certificate Invitation letter Conference kit

Your details

We only need what's required to register and email your confirmation. Everything else is optional.

For Support Please Contact

Coupon code

Have a code? Apply it here — the discount updates the total immediately.

Apply
VISA MC AMEX UPI

Payments encrypted & processed securely. Refundable up to 14 days before the event.

Registration summary

ConferenceICHMCR
ModeStandard / Physical
ParticipationListener
Registration fee$—
Bank charges (5.8%)$—
Discount-$0.00
Total payable $—

Includes all bank processing charges — the amount above is exactly what will be charged. View charge breakdown

Need help?

Contact our registration team:

Benefits of Registering as Listener
Access to Conference Sessions
Networking Opportunities
Certificate of Participation
Invitation Letter Support
Conference Kit / Materials
Access to Keynote Sessions
Conference Session Tracks
SDG Wheel

SDG-Aligned Research Themes

International Conference on Hematologic Malignancies and Cancer Research conference tracks support global knowledge exchange, innovation, and sustainable development priorities across diverse disciplines.

SDG 3 - Good Health and Well-being SDG 4 - Quality Education SDG 9 - Industry, Innovation and Infrastructure SDG 10 - Reduced Inequalities

This session will explore the latest innovations in molecular diagnostics that enhance the detection and characterization of hematologic malignancies. Emphasis will be placed on the integration of genomic technologies and their impact on patient management.

This track will focus on the design and implementation of clinical trials specifically targeting hematologic cancers. Discussions will include novel therapeutic agents, trial methodologies, and the ethical considerations involved.

This session will highlight recent discoveries in biomarkers that have the potential to revolutionize diagnosis and treatment in hematologic malignancies. Participants will discuss the implications of these findings for personalized medicine.

This track will examine the critical role of translational research in advancing therapeutic strategies for hematologic malignancies. It will showcase successful case studies where laboratory findings have directly influenced clinical practice.

This session will address the importance of patient-centered approaches in the treatment of hematologic malignancies. Topics will include shared decision-making, quality of life assessments, and supportive care strategies.

This track will focus on the latest therapeutic strategies being developed for hematologic cancers, including targeted therapies and immunotherapies. Experts will discuss the mechanisms of action and clinical outcomes associated with these treatments.

This session will showcase cutting-edge laboratory techniques and technologies that are transforming hematology research. Emphasis will be placed on high-throughput screening, CRISPR technology, and bioinformatics applications.

This track will delve into the epidemiological trends and risk factors associated with various hematologic malignancies. Discussions will include genetic predispositions, environmental influences, and lifestyle factors.

This session will focus on the specific challenges faced in the diagnosis and treatment of hematologic malignancies in pediatric populations. Experts will share insights on tailored therapeutic approaches and long-term outcomes.

This track will explore the integration of conventional treatments with alternative therapies in the management of hematologic malignancies. The session will highlight evidence-based practices and patient outcomes.

This session will provide an overview of emerging trends and future directions in hematology research. Participants will discuss the potential impact of artificial intelligence, big data, and novel therapeutic modalities on the field.

COPYRIGHT © 2026 International Conference on Hematologic Malignancies and Cancer Research. ALL RIGHTS RESERVED